Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Alcohol Dehydrogenase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel enzyme mutant enables high-purity drug intermediate synthesis with improved conversion rates and industrial scalability for global supply chains.
Patent CN112481226A discloses solvent-tolerant ADH mutants enabling 99.9% conversion for chiral diaryl alcohols, offering a green alternative to costly chemical synthesis.
Patent CN105543186A reveals novel biocatalytic route for high-purity chiral alcohols. Enables cost reduction in chiral alcohol manufacturing and supply chain reliability.
Patent CN105543186A enables high-purity chiral alcohol production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN115011573B enables efficient synthesis of chiral alcohols with high substrate loading and reduced cofactor costs for pharmaceutical supply chains.
Patent CN109943542A reveals enhanced ADH for Atazanavir. Lower cost, green synthesis, high purity pharmaceutical intermediates for global supply chains.
Novel TbSADH mutants enable high-yield synthesis of chiral biaryl alcohols. Efficient biocatalysis for pharmaceutical intermediates with superior stereoselectivity.
Patent CN114277006B reveals a novel ADH for synthesizing chiral heterocyclic alcohols without organic solvents, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN104805142A enables high-purity Tomoxetine via enzyme catalysis. Reduces cost and improves supply chain reliability for pharmaceutical intermediates manufacturing.